Lexicon Pharmaceuticals, Inc.
HealthcareNASDAQ:LXRX · NASDAQ Global Select
+$0.03 today
Vol 2.99M · Avg 2.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$69.6M of revenue converted into -$26.1M of net income for the selected period. Gross margin is 98.2% and net margin is -91.6%, showing how much revenue survives after costs and taxes. EPS is $-0.07, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M +60.2% | $31.1M +2481.5% | $1.2M +766.2% | $139.0K -53.4% | $298.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $274.0K -55.5% | $616.0K -99.0% | $59.0M +12.3% | $52.5M -4.6% | $55.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $49.5M +62.6% | $30.5M +152.7% | -$57.8M -10.3% | -$52.4M +4.3% | -$54.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.4% +1.4pp | 98.0% +4896.0pp | -4798.0% +32883.3pp | -37681.3% -19309.5pp | -18371.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $61.1M -27.7% | $84.5M +43.5% | $58.9M +11.5% | $52.8M -4.1% | $55.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $37.3M -71.7% | $131.9M | $0 | $0 | $0 | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $98.4M -56.7% | $227.6M +99.7% | $114.0M +135.6% | $48.4M +49.6% | $32.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $621.0K +16.3% | $534.0K -3.6% | $554.0K +29.7% | $427.0K +46.2% | $292.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.4M +77.5% | -$184.3M -8.6% | -$169.8M -69.7% | -$100.0M -15.4% | -$86.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -83.1% +509.8pp | -592.9% +13506.4pp | -14099.3% +57866.9pp | -71966.2% -42884.3pp | -29081.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$48.9M +75.2% | -$197.1M -14.8% | -$171.8M -70.5% | -$100.8M -15.7% | -$87.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -98.2% +536.0pp | -634.2% +13630.7pp | -14265.0% +58224.3pp | -72489.2% -43264.4pp | -29224.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.9M -43.8% | $12.3M +59.0% | $7.7M +384.5% | $1.6M +1091.0% | $134.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.3M -46.5% | $15.6M +18.9% | $13.1M +371.3% | $2.8M +246.6% | $802.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.4M +56.5% | -$3.3M +38.8% | -$5.4M -353.5% | -$1.2M -77.2% | -$668.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$50.3M +74.9% | -$200.4M -13.1% | -$177.1M -73.7% | -$101.9M -16.2% | -$87.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -101.1% +543.7pp | -644.8% +14066.1pp | -14710.9% +58630.1pp | -73341.0% -43892.0pp | -29449.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$50.3M +74.9% | -$200.4M -13.1% | -$177.1M -73.7% | -$101.9M -16.2% | -$87.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -101.1% +543.7pp | -644.8% +14066.1pp | -14710.9% +58630.1pp | -73341.0% -43892.0pp | -29449.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +77.8% | -$1 +21.3% | -$1 -29.0% | -$1 -1.6% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +77.8% | -$1 +21.3% | -$1 -29.0% | -$1 -1.6% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $363.1M +13.4% | $320.0M +44.7% | $221.1M +33.4% | $165.7M +13.8% | $145.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $363.1M +13.4% | $320.0M +44.7% | $221.1M +33.4% | $165.7M +13.8% | $145.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Gossamer Bio, Inc.
GOSS
$38.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LXRX generate?
Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.80M of revenue in fiscal 2025.
Is LXRX profitable?
Lexicon Pharmaceuticals, Inc. (LXRX) reported -$50,341,000.00 of net income, with a net margin of -101.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.